Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy

摘要: There is wide variability in the response of individuals to standard doses drug therapy. This an important problem clinical practice, where it can lead therapeutic failures or adverse events. Polymorphisms genes coding for metabolizing enzymes and transporters affect efficacy toxicity. Pharmacogenomics aims identify predisposed high risk toxicity low from anticancer drugs. chapter focuses on significance polymorphisms drug-metabolizing influencing The most examples demonstrate influence pharmacogenomics therapy are thiopurine methyltransferase (TPMT), UGT (uridine diphosphate glucuronosyltransferase) 1A1*28, DPD (dihydropyrimidine dehydrogenase) *2A, respectively, 6-mercaptopurine, irinotecan, 5-fluorouracil However, other therapies no clear association has been found pharmacokinetics pharmacodynamics Evaluation different regimens tumor types showed that have different, sometimes even contradictory, pharmacokinetic pharmacodynamic effects tumors application cancer treatment therefore requires more detailed information regarding transporters. A greater understanding complexities needed before individualized be applied a routine basis.